³¼ÒÁ¾¾ç¿¡¼ÀÇ Melanoma Antigen Gene (MAGE) ¿Í Synovial Sarcoma on X chromosome (SSX)ÀÇ ¹ßÇö
Expression of Melanoma Antigen Gene (MAGE) and Synovial Sarcoma on X chromosome (SSX) in Ovarian Tumors
±è¿µ¿Á, ¹ÚÁ¾¿í, ÀåÈñ°æ, ¹ÚÁø°æ, ±è±¤ÈÖ, Àüâȣ, ±è¿ø,
¼Ò¼Ó »ó¼¼Á¤º¸
±è¿µ¿Á ( Kim Young-Ok )
°í½Å´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
¹ÚÁ¾¿í ( Park Jong-Wook )
°è¸í´ëÇб³ ÀÇ°ú´ëÇÐ ¸é¿ªÇб³½Ç
ÀåÈñ°æ ( Chang Hee-Kyung )
°í½Å´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
¹ÚÁø°æ ( Park Jean-Kyung )
°í½Å´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
±è±¤ÈÖ ( Kim Kwang-Hui )
°í½Å´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
Àüâȣ ( Jeon Chang-Ho )
´ë±¸°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ Áø´Ü°Ë»çÀÇÇб³½Ç
±è¿ø ( Kim Won )
°æ³²Á¤º¸´ëÇÐ Àǹ«ÇàÁ¤°ú
KMID : 0357920040380060372
Abstract
Background: Several cancer-testis antigen genes or gene families have been isolated to date, including Melanoma Antigen Gene (MAGE) and Synovial Sarcoma on X chromosome (SSX). This study attempted to investigate the possibility of immunotherapy for ovarian cancer and to explore the prevalence of the expression of MAGE and SSX.
Methods: The fresh tissue samples were obtained from 5 cases of normal ovaries, 6 cases of non-neoplastic disease, 21 cases of benign ovarian tumors, and 12 cases of malignant ovarian tumors. The expression of MAGE A1-6 and SSX 1-9 was detected by nested reverse transcription-polymerase chain reaction using each common primers sets for MAGE A1-6 and SSX 1-9.
Results: The expression rate of MAGE 1-6 mRNA was 23.0% (5/21) for the benign ovarian tumors and 91.7% (11/12) for the malignant ovarian tumor, whereas the normal ovaries (0/5) and non-neoplastic ovarian tissues (0/6) did not express MAGE (p<0.05). The expression rate of SSX was 40.0% (2/5) for the normal ovaries, 23.0% (5/21) for the benign ovarian tumors, and 33.3% (4/12) for the malignant ovarian tumors, while the non-neoplastic ovarian tissues showed no expression of SSX (p>0.05). A relationship between the two genes was not observed (kappa coefficient=0.32).
Conclusions: These results suggest that the gene products of MAGE and SSX can be useful for the immunotherapy of ovarian cancer patients and that MAGE can be a more promising target than SSX from the viewpoint of applicability and cancer-specificity.
Å°¿öµå
Ovarian cancer;MAGE;SSX;Common primers
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸